Securities code: Tibet Duo Rui Pharmaceutical Co.Ltd(301075) securities abbreviation: Tibet Duo Rui Pharmaceutical Co.Ltd(301075) Announcement No.: 2022024 Tibet Duo Rui Pharmaceutical Co.Ltd(301075)
Announcement on the addition of directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Tibet Duo Rui Pharmaceutical Co.Ltd(301075) (hereinafter referred to as “the company”) held the 11th meeting of the first board of directors on March 23, 2022, deliberated and approved the proposal on nominating candidates for non independent directors of the first board of directors and the proposal on nominating candidates for independent directors of the first board of directors. The board of directors of the company agreed to nominate Ms. Jin Fen as a candidate for non independent directors of the first board of directors of the company, Mr. Wang Yunguo is nominated as the candidate for independent director of the first board of directors of the company. The resumes of the above candidates are shown in the annex.
As of the disclosure date of this announcement, Mr. Wang Yunguo has not obtained the qualification certificate of independent director. He has made a written commitment to participate in the latest independent director training organized by Shenzhen Stock Exchange and to obtain the qualification certificate of independent director recognized by Shenzhen Stock Exchange. Candidates for independent directors need to be submitted to Shenzhen stock exchange for filing and review, and can be submitted to the general meeting of shareholders for deliberation only after there is no objection.
The nomination committee of the board of Directors examined the qualifications of the above-mentioned candidates for directors and considered that the above-mentioned candidates for directors of the first board of directors met the qualifications of directors specified in relevant laws and regulations. The current independent directors of the company have expressed their consent on the nomination of candidates for non independent directors and independent directors of the first board of directors of the company. The number of candidates for the above-mentioned directors complies with the provisions of the company law and other laws and regulations and the articles of association. Among them, the proportion of candidates for independent directors is not less than one-third of the members of the board of directors, and the total number of proposed directors who concurrently hold the positions of general manager or other senior managers of the company is not more than one-half of the total number of directors of the company. The above candidates for directors need to be submitted to the general meeting of shareholders for deliberation and elected by non cumulative voting system.
In order to ensure the normal operation of the board of directors, before the appointment of additional directors, the directors of the company shall still earnestly perform their duties as directors in accordance with the provisions of laws, administrative regulations, departmental rules, normative documents and the articles of association, and shall not commit any act detrimental to the interests of the company and shareholders. It is hereby announced.
Tibet Duo Rui Pharmaceutical Co.Ltd(301075) board of directors March 24, 2022 Annex:
Tibet Duo Rui Pharmaceutical Co.Ltd(301075)
Resume of candidates for the first board of directors
Jin Fen, female, born in September 1980, Chinese nationality, without overseas permanent residency, registered corporate financial planner and Bachelor degree. From May 2002 to June 2013, served as the financial manager of Wuhan boruijia Technology Co., Ltd; From July 2013 to August 2019, served as the financial manager of Hubei banruijia Technology Co., Ltd; From December 2016 to November 2017, he served as the supervisor of Duorui Co., Ltd; From December 2017 to April 2019, served as the chief financial officer of Duorui Co., Ltd; From May 2019 to February 2020, served as deputy general manager and Secretary of the board of directors of dorui Co., Ltd; From February 2020 to now, he has served as Tibet Duo Rui Pharmaceutical Co.Ltd(301075) deputy general manager and Secretary of the board of directors.
Wang Yunguo, male, born in December 1972, has a bachelor’s degree, a Chinese certified public accountant, Chinese nationality and no permanent right of residence abroad. From July 1995 to October 2000, he worked in vitality 28 group company and once served as the chief of the finance section; From October 2000 to October 2002, he worked in Daxin certified public accountants, and once served as the audit project manager; From October 2002 to December 2013, he served as the accounting manager of Valeo automotive air conditioning (Hubei) Co., Ltd; From January 2004 to June 2012, he served as the finance minister of Ningbo siweier automobile decoration Co., Ltd; From June 2012 to September 2021, he worked in Changjiang Growth Capital Investment Co., Ltd. and once served as the head of risk control and fund manager; From October 2021 to now, he served as deputy general manager and compliance risk control director of Hubei Fengze Private Equity Fund Management Co., Ltd.
